Biotechnology

Humacyte

Humacyte released FY2026 Q1 earnings on May 13 Pre-Market (EST), actual revenue USD 495K (forecast USD 1.465M), actual EPS USD -0.09 (forecast USD -0.1161)

Humacyte to Release FY2026 Q1 Earnings on May 13 Pre-Market EST, Forecast Revenue USD 1.465 M, EPS USD -0.1161

Humacyte released FY2025 annual earnings on March 27 Pre-Market (EST), actual revenue USD 2.038 M (forecast USD 2.843 M), actual EPS USD -0.26 (forecast USD -0.278)

Humacyte released FY2025 Q4 earnings on March 27 Pre-Market (EST), actual revenue USD 467K (forecast USD 1.349M), actual EPS USD -0.1327 (forecast USD -0.1284)

Humacyte to Release FY2025 Q4 Earnings on March 27, Pre-Market EST; Forecast Revenue USD 1.349 M, EPS USD -0.1316

Humacyte Inc. Announces Long-term Success of Symvess in Limb Arterial Trauma Repair

D. Boral Capital Reiterates Buy Rating on Humacyte Stock

Humacyte released FY2025 Q3 earnings on November 12 During-Market EST, actual revenue USD 753 K (forecast USD 922.83 K), actual EPS USD -0.1106 (forecast USD -0.1583)

Humacyte released FY2025 9 Months Earnings on November 12 During-Market EST, Actual Revenue: USD 1.571 M, Actual EPS: USD -0.0732

Humacyte to Release FY2025 Q3 Earnings on November 12 During-Market (EST), Forecast Revenue USD 922.83 K, EPS USD -0.1583

Humacyte released FY2025 Q2 earnings on August 11 Pre-Market (EST), actual revenue USD 301K (forecast USD 1.004M), actual EPS USD -0.2422 (forecast USD -0.1616)

Humacyte released FY2025 Semi-Annual earnings on August 11 Pre-Market (EST), actual revenue USD 818K, actual EPS USD 0.0099

Humacyte to Release FY2025 Q2 Earnings on August 11 Pre-Market EST, Forecast Revenue USD 1.004 M, EPS USD -0.1616

Humacyte Inc. Annual Shareholders' Meeting Approves Director Elections and Increase in Authorized Common Stock

D. Boral Capital Reiterates Buy Rating on Humacyte

Humacyte's Novel Vascular Therapy Significantly Superior to Autologous AVF

Benchmark Downgrades HUMACYTE INC Target Price

Humacyte released FY2025 Q1 earnings on May 13 During-Market EST, actual revenue USD 517 K (forecast USD 764.83 K), actual EPS USD 0.2795 (forecast USD -0.19)

Humacyte Reports 2025 Q1 Earnings

Humacyte Inc reports quarterly earnings, loss of 19 cents per share

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

HUMA

Humacyte entered an underwriting agreement to sell 47.6 million shares at $1.05 each, raising approximately $46.8 million in net proceeds. Underwriters have a 30-day option to purchase up to 7.1 million additional shares. The offering is expected to close around June 12, 2026.

TradingView

Barclays

Humacyte - CW27

Humacyte Enters Underwriting Agreement for 47.6M-Share Offering at $1.05, Nets ~$46.8M

Humacyte (HUMA) stock fell 22% despite positive Phase 3 trial data for its ATEV product, which met primary endpoints with significant clinical benefits. The decline was driven by a dilutive $50 million public offering priced at $1.05 per share to fund commercialization and development.

benzinga_article

Incyte

Shutterstock

Why Is Humacyte Stock Falling Thursday?

PPCB

PPBT

SXTP

ATOS

SXTPW

QUCY

In Thursday's pre-market session, several healthcare stocks showed significant volatility. Gainers included Propanc Biopharma (+52.6%), 60 Degrees (+16.66%), and Quantum Cyber (+16.14%). Conversely, notable losers were Atossa Therapeutics (-26.1%), Purple Biotech (-23.46%), and Humacyte (-20.9%). The report highlights specific price movements and market capitalizations for these companies during the early trading hours.

Propanc Biopharma

Purple Biotech

60 Degrees Pharmaceuticals

Atossa Therapeutics

60 DEGREES PHARMACEUTICALS INC C/WTS 12/07/2028 (TO PUR COM)

Quantum Cyber NV

Silexion Therapeutics

Genenta Science S.P.A.

CEL-SCI

GlucoTrack

Aditxt

Basel Medical

PROPANC BIOPHARMA INC

Mainz Biomed NV

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM)

12 Health Care Stocks Moving In Thursday's Pre-Market Session

ORCL

.SPX

Several stocks, including Humacyte (-17.9%), PureCycle Technologies (-14.5%), Oracle (-7.2%), and Oxford Industries (-6.6%), are gapping down in premarket trading on Thursday. Despite these declines, stock index futures (SPX) rose as Washington announced the completion of strikes against Iran.

- Stocks are exhibiting gap-down moves ahead of Thursday's market opening.  
- Notable declines include Humacyte down 17.9%, PureCycle Technologies down 14.5%, and Oracle down 7.2%.  
- The overall stock index futures were higher due to Washington's announcement of completed strikes against Iran.

Oracle

Oxford Industries

S&P 500

PureCycle Tech

Defiance Daily Target 2X Long ORCL ETF

SPDR S&P 500

iShares Core S&P 500

VG S&P 500

SPDR Portfolio S&P 500 ETF

Direxion S&P 500 Bull 3X

Pro UltrPro S&Pro 500

Ultr S&P 500 Pro

Pro Shrt S&P 500

Direxion S&P 500 Bear 3X

Pro UltrPro Shrt S&Pro 500

ORACLE CORP DEPOSITARY SH REP 1/2000TH PFD SER D

At a glance: Stocks gapping down premarket

BARC

Humacyte, Inc. (Nasdaq: HUMA) announced the pricing of an underwritten public offering of 47,619,048 shares of common stock at $1.05 per share, raising approximately $50 million in gross proceeds. The closing is expected around June 12, 2026. Net proceeds will fund the commercialization of Symvess®, BLA supplement filing, pipeline development, and working capital. Barclays, BTIG, and Titan Partners are joint book-running managers.

StockTitan

Broadridge Financial Solution

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock | HUMA Stock News

Humacyte's bioengineered blood vessel met its primary endpoint in a Phase 3 trial for dialysis access, showing 91 more catheter-free days than the standard of care. The company will end enrollment and file a BLA supplement with the FDA in H2. Additionally, Humacyte commenced an underwritten public offering of common stock to fund commercialization of Symvess and pipeline development.

MorningStar

Humacyte's Bioengineered Blood Vessel Hits Primary Endpoint in Phase 3 Trial